Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX43 in HR-positive, HER2-negative advanced or metastatic breast cancer after progression on standard therapy
CTR20260692Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in breast cancer, sponsored by HyBioPharma. Started Apr 2026; status: active.
02
Drugs
HLX43
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20260692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260692.